Jesper D. Gunst

MD PhD working on clinical trials in #HIV using #bNAbs, #LRAs and/or #TLR agonists.

[Jesper D. Gunst @JesperGunst]

@EATGx @HIVGlasgow It was a pleasure to be part of this workshop. Thank you!

[Christian Gaebler @c_gaebler]

🚨 We’re hiring! 🚨
Join the Gaebler & Ibrahim Labs for an exciting postdoc position at the intersection of virology & gene regulation! Help us uncover mechanisms behind HIV latency using cutting-edge genome engineering. More info: https://t.co/Lu2MilbHmE

[EACS @EACSociety]

Exciting news! Our survey report with
@ECDC_EU on #HIV #stigma in the #healthcare setting is now available.

Huge thanks to everyone who contributed to its success!

👉https://t.co/b1gJZ6p1xL

Don't miss the presentation on Friday by @TeyNoori at #AIDS2024

[Jesper D. Gunst @JesperGunst]

@JillianLau1 Haha! I try to follow you, but I can’t keep up 🥳

[Jesper D. Gunst @JesperGunst]

@JillianLau1 Time to detectable viremia = first pVL >50 copies/ml

Time to loss of virologic control = ART restart or two consecutive pVL >= 5,000 copies/ml

👌🏻

[Ming Lee @jnim87]

Vibeke Klastrup presenting metanalysis of ATI studies showing smaller reservoir size and interventions such as #bNAbs are associated with duration of viral control during treatment interruptions.
#AIDS2024

[Jesper D. Gunst @JesperGunst]

@tristanjbarber @sandulescu_oana @MartaVasylyev @NachoBernardino @AgnesLibois @MariaMazzitell4 @EACSociety Fantastic!

[Oana Sandulescu @sandulescu_oana]

How to interpret and how to manage low level viremia? Hearing now from @JesperGunst with important insight from amazing session chair @Rokx1 at #YINGconf24

[Jillian Lau @JillianLau1]

Onto my fave topic - analytical treatment interruptions: where ART is stopped in an #HIVcure study.

Viral rebound.

Tongcui Ma showed T cell features (pic 1) and Mauro Garcia showed IgG antibodies (pic 2) impacted time to viral rebound.

Use as biomarkers for TVR?
#CROI2024

[Jesper D. Gunst @JesperGunst]

@JillianLau1 Thanks, Jill 🤟🏻

[EACS @EACSociety]

The survey on "Measuring #HIV knowledge and attitudes in the #healthcare setting" is still available until 5 Dec!

Complete it today or spread the word in your network. 🔄

Available in 38+ languages! 🌍

Survey link: https://t.co/FxThqDHwnV
@ECDC_EU

[Jesper D. Gunst @JesperGunst]

@c_gaebler @ChariteBerlin Congrats, Christian! 👌🏻

[NEJM Evidence @NEJMEvidence]

Editorial: “Host Receptor Targeting to Treat #Covid19” by @JesperGunst and Ole Schmeltz Søgaard https://t.co/SaOv3GWzau

#SARSCov2 #InfectiousDisease @AarhusUni_int @AUHdk @syctong @Josh_S_Davis @jasonroberts_pk

[EATG @EATGx]

If you work in a healthcare setting in Europe or Central Asia, you are invited to take this survey on stigma & discrimination by @ECDC_EU and @EACSociety
⏲️ Deadline: 30 November 2023
#StigmaFree

[NEJM Evidence @NEJMEvidence]

Inhibition of intracellular enzymes like TMPRSS2 that are vital for replication of #SARSCoV2 may be an effective treatment strategy for #COVID19. Gunst and Sogaard comment on recent clinical evidence for the effect of TMPRSS2 inhibitors like nafamostat. https://t.co/SaOv3GWzau

[Christian Gaebler @c_gaebler]

Exciting news! The Berlin Institute of Health at Charité @berlinnovation is launching its BIH PhD Program, focused on medical translation and innovation.
🌟 Fully funded doctoral positions for translational projects
🌟 Open for applications until Nov 22
https://t.co/5trDu8pVoK

[Jesper D. Gunst @JesperGunst]

@ECDC_EU @ECDC_HIVAIDS @EACSociety

[Jesper D. Gunst @JesperGunst]

European AIDS Clinical Society (EACS) vil undersøge viden og holdninger om HIV blandt sundhedsfaglige på tværs af Europa.

Så hvis du har ca. 10 min til at udfylde - vil vi blive glade!

@Sygeplejeraadet @laegeforeningen @Sundpol @regionerne

https://t.co/ftw7zJS4tj

[Nature Medicine @NatureMedicine]

In people with HIV-1 undergoing antiretroviral treatment interruption, lefitolimod + broadly neutralizing antibodies did not delay viral rebound more than antibodies alone, raising questions of how to optimize combination immunotherapy to control HIV-1 https://t.co/7vjcwniEVT

[Jesper D. Gunst @JesperGunst]

Review on Immunomodulation with IL-7 and IL-15 in #HIV-1 infection.

@viruseradicate

https://t.co/e3JH3rm3m7